Reverse Amide Compounds for Selective HDAC6 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HDAC inhibitors lack selectivity and potency for specific classes or individual members of the histone deacetylase (HDAC) family, particularly HDAC6, which is crucial for aggresome formation and cellular viability, especially in cancer cells, and there is a need for more effective therapeutic agents for cancer and neurodegenerative disorders.
Innovation Solution
Development of novel compounds with specific structures that act as potent and selective inhibitors of HDAC6, capable of inhibiting HDAC activity, inducing apoptosis in cancer cells, and disrupting aggresome formation, including pharmaceutical compositions and methods for their use in treating diseases mediated by HDAC6.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current HDAC inhibitors are used, then HDAC activity is inhibited, but selectivity for specific HDAC family members (particularly HDAC6) is insufficient
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features that target particular HDAC family members. The compounds contain modified amide groups and specific substituent patterns (R1-R6 groups) that create localized interactions with HDAC6's active site, enabling selective inhibition while maintaining catalytic blockade. This allows the inhibitor to distinguish HDAC6 from other HDAC isoforms through targeted molecular recognition.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor structure, including the amide group modifications, aromatic ring substitutions, and side chain lengths. These parameter variations tune the binding affinity and selectivity profile, allowing optimization for HDAC6 while reducing off-target effects on other HDAC family members.
2Reliability
If current HDAC inhibitors are used, then HDAC activity is inhibited, but potency is insufficient
Solution Approach 1:
The patent achieves enhanced potency through parameter changes in the molecular structure, specifically optimizing the amide group parameters, aromatic ring parameters, and side chain parameters. These changes increase binding affinity to HDAC6, resulting in more potent inhibition at lower concentrations while maintaining reasonable structural complexity for drug development.
Solution Approach 2:
The patent utilizes composite molecular structures combining multiple functional elements: a core amide group, aromatic ring systems, and various substituent groups (R1-R6). This composite approach creates a multifaceted interaction profile with HDAC6, enhancing potency through multiple simultaneous binding interactions rather than relying on a single structural feature.
3Productivity
If non-selective HDAC inhibitors are used, then broad HDAC activity is inhibited, but specific therapeutic effect on HDAC6-mediated diseases is reduced
Solution Approach 1:
The patent applies local quality by incorporating specific structural motifs that create localized binding interactions with HDAC6's unique active site architecture. The modified amide groups and specific substituent patterns engage in localized hydrogen bonding and hydrophobic interactions that are characteristic of HDAC6, thereby enhancing therapeutic efficacy for HDAC6-mediated diseases while minimizing off-target effects on other HDAC isoforms with different active site configurations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate selective inhibition of HDAC6, effectively inducing apoptosis in cancer cells and treating diseases related to HDAC6, offering improved therapeutic options for cancers and neurodegenerative disorders.
Implementation Method 1
The compounds demonstrate selective inhibition of HDAC6, effectively inducing apoptosis in cancer cells
Data Source
AI summary
The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.